Becton Dickinson said on Wednesday that its Chief Financial Officer Chris DelOrefice will depart the company, effective December 5, to pursue a new professional opportunity. The company said it is ...

Key Insights The projected fair value for Becton Dickinson is US$341 based on 2 Stage Free Cash Flow to Equity ...

Becton Dickinson said on Wednesday that its Chief Financial Officer Chris DelOrefice will depart the company, effective December 5, after four years at the medical device maker.

Becton, Dickinson and Company has seen years of stagnation in its business and shares. Despite a return to solid growth this year, the company's performance has been mediocre over the long haul, and ...

Becton Dickinson ( ($BDX) ) has issued an announcement. On October 15, 2025, BD announced a CFO transition plan as Chris ...

Becton Dickinson CFO Chris DelOrefice will step down Dec. 5 as BD reports strong fiscal 2025 sales and appoints Vitor Roque interim CFO.

Detailed price information for Becton Dickinson and Company (BDX-N) from The Globe and Mail including charting and trades.

Oakmark Funds, advised by Harris Associates, released its “Oakmark Global Fund” second quarter 2025 investor letter. The fund underperformed its benchmark, the MSCI World Index (net), in the second ...

Becton, Dickinson and Co. (NYSE:BDX) is a multinational medical technology company that manufactures and sells medical ...

With a market cap of $64 billion, Franklin Lakes, New Jersey-based Becton, Dickinson and Company (BDX) is a global medical technology leader. Operating through three key segments: BD Medical; BD Life ...

Testing companies have revealed little about how their products perform in minors. That could be a problem. By Katherine J. Wu The reversal came just hours after the federal government threatened the ...